Literature DB >> 28400899

How a CT-Direct Protocol at an American Comprehensive Stroke Center Led to Door-to-Needle Times Less Than 30 Minutes.

Lisa M Caputo1, Judd Jensen2, Michelle Whaley2, Mark J Kozlowski3, Christopher V Fanale2, Jeffrey C Wagner2, Alessandro Orlando1, David Bar-Or1.   

Abstract

BACKGROUND AND
PURPOSE: The safety and efficacy of intravenous tissue plasminogen activator (IV tPA) following acute ischemic stroke (AIS) is dependent on its timely administration. In 2014, our Comprehensive Stroke Center designed and implemented a computed tomography-Direct protocol to streamline the evaluation process of suspected patients with AIS, with the aim of reducing door-to-needle (DTN) times. The objectives of our study were to describe the protocol development and implementation process, and to compare DTN times and symptomatic intracranial hemorrhage (sICH) rates before and after protocol implementation.
METHODS: Data were prospectively collected for patients with AIS receiving IV tPA between January 1, 2010, and May 31, 2015. The DTN times, examined as median times and time treatment windows, and sICH rates were compared pre- and postimplementation.
RESULTS: Two hundred ninety-five patients were included in the study. After protocol implementation, median DTN times were significantly reduced (38 vs 28 minutes; P < .001). The distribution of patients treated in the three time treatment windows described below changed significantly, with an increase in patients with DTN times of 30 minutes or less, and a decrease in patients with DTN times 31 to 60 minutes and over 60 minutes (P < .001). There were two cases of sICH prior to implementation and one sICH case postimplementation.
CONCLUSIONS: The implementation of a protocol that streamlined the processing of suspected patients with AIS significantly reduced DTN time without negatively impacting patient safety.

Entities:  

Keywords:  acute stroke; door-to-needle time; evidence-based medicine; ischemic stroke; tissue-type plasminogen activator

Year:  2016        PMID: 28400899      PMCID: PMC5382655          DOI: 10.1177/1941874416672783

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  11 in total

1.  24/7 Neurocritical Care Nurse Practitioner Coverage Reduced Door-to-Needle Time in Stroke Patients Treated with Tissue Plasminogen Activator.

Authors:  Jennifer L Moran; Kazuma Nakagawa; Susan M Asai; Matthew A Koenig
Journal:  J Stroke Cerebrovasc Dis       Date:  2016-02-19       Impact factor: 2.136

2.  Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator.

Authors:  Bijoy K Menon; Jeffrey L Saver; Shyam Prabhakaran; Mathew Reeves; Li Liang; Daiwai M Olson; Eric D Peterson; Adrian F Hernandez; Gregg C Fonarow; Lee H Schwamm; Eric E Smith
Journal:  Stroke       Date:  2012-07-17       Impact factor: 7.914

3.  Reducing in-hospital delay to 20 minutes in stroke thrombolysis.

Authors:  Atte Meretoja; Daniel Strbian; Satu Mustanoja; Turgut Tatlisumak; Perttu J Lindsberg; Markku Kaste
Journal:  Neurology       Date:  2012-05-23       Impact factor: 9.910

4.  Time is brain--quantified.

Authors:  Jeffrey L Saver
Journal:  Stroke       Date:  2005-12-08       Impact factor: 7.914

5.  Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.

Authors:  Gregg C Fonarow; Eric E Smith; Jeffrey L Saver; Mathew J Reeves; Deepak L Bhatt; Maria V Grau-Sepulveda; DaiWai M Olson; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm
Journal:  Circulation       Date:  2011-02-10       Impact factor: 29.690

6.  Do efforts to decrease door-to-needle time risk increasing stroke mimic treatment rates?

Authors:  Ava L Liberman; Eric M Liotta; Fan Z Caprio; Ilana Ruff; Matthew B Maas; Richard A Bernstein; Rahul Khare; Deborah Bergman; Shyam Prabhakaran
Journal:  Neurol Clin Pract       Date:  2015-06

7.  Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study.

Authors:  J R Marler; B C Tilley; M Lu; T G Brott; P C Lyden; J C Grotta; J P Broderick; S R Levine; M P Frankel; S H Horowitz; E C Haley; C A Lewandowski; T P Kwiatkowski
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

8.  Safety of intravenous thrombolysis in stroke mimics: prospective 5-year study and comprehensive meta-analysis.

Authors:  Georgios Tsivgoulis; Ramin Zand; Aristeidis H Katsanos; Nitin Goyal; Ken Uchino; Jason Chang; Efthimios Dardiotis; Jukka Putaala; Anne W Alexandrov; Marc D Malkoff; Andrei V Alexandrov
Journal:  Stroke       Date:  2015-03-19       Impact factor: 7.914

Review 9.  Stroke Mimics and Acute Stroke Evaluation: Clinical Differentiation and Complications after Intravenous Tissue Plasminogen Activator.

Authors:  Peggy L Nguyen; Jason J Chang
Journal:  J Emerg Med       Date:  2015-03-20       Impact factor: 1.484

10.  Effective management of patients with acute ischemic stroke based on lean production on thrombolytic flow optimization.

Authors:  Zhuoyuan Liang; Lijie Ren; Ting Wang; Huoyou Hu; Weiping Li; Yaping Wang; Dehong Liu; Yi Lie
Journal:  Australas Phys Eng Sci Med       Date:  2016-04-19       Impact factor: 1.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.